Immunowake closes $20M in pre-Series A

Shanghai, China - 15th May 2022. Immunowake has raised $20M in pre-series A financing.

This funding round was led by Hyfinity Investments, followed by South China Venture, Lapam Capital, and HEDA Ventures. To date, Immunowake has raised $23.5M. Hyfinity Investments will join the board of directors as part of the financing.

The funds raised in this round will be used to accelerate our cytokine pipeline through pre-IND studies and Phase I clinical trials. We expect the submit our first IND application by the last quarter of 2025.

“We are excited to have such a strong group of investors backing our company at this stage. This represents strong confidence in our technology. Our bi-specific antibody platform has the capacity to solve the issues that have been long been plaguing cytokine therapy,” says Xiaoyun Wu, CEO and founder of Immunowake.

About Immunowake

Immunowake is a pre-clinical stage company focused on the development of bi-specific antibodies for cancer therapy. Immunowake utilizes its novel platforms to design multi-specific antibodies with unique mechanisms of action.